ArticleJournal for immunotherapy of cancer2025
Multiomics elucidation of surrounding AT2 cells impeding tertiary lymphoid structures function in neoadjuvant chemoimmunotherapy response of multiple primary lung cancers.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Evolution of Spatial Omics Technologies Introduces A Novel Avenue for Lung Cancer Research.Genomics, proteomics & bioinformatics · 2026Review
- Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inconsistent immunotherapy response among lesions in patients with multiple primary lung cancer (MPLC) remains poorly understood, presenting a significant challenge for effective treatment. In this study, we conducted a comprehensive multiomics analysis of all lesions from a patient with MPLC who exhibited varied responses to neoadjuvant chemoimmunotherapy. Further verification was conducted through external single-cell data and multiplex immunohistochemistry of three cases of MPLC.Notably, tertiary lymphoid structures (TLSs) were observed across all nodules, regardless of response, suggesting possible TLS impairment in non-responsive nodules. Cell neighborhood (CN) analysis revealed that type II alveolar epithelial cell (AT2) cell-positive CNs were prevalent in non-responsive nodules, while AT2-negative CNs appeared in responsive nodules, strongly associating AT2 cell presence with a reduced therapeutic response. Spatial colocalization analysis further showed that AT2 cells surrounding TLSs upregulated immunosuppressive markers on B cells within TLSs. The mechanism of this suppressive effect was further unveiled that macrophage migration inhibitory factor (MIF), secreted by AT2 cells, binds to sialic acid acetylesterase (SIAE) receptors on B cells by single-cell RNA sequencing analysis, which were validated in four additional non-responsive nodules from three other patients with MPLC. Multiomics analysis revealed AT2 cells exert immunosuppressive effects by inhibiting B cells within TLS through MIF-SIAE signaling axis in patients with MPLC. These findings offered new perspectives for tailored immunotherapy for patients with MPLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.